Pharming Group N.V. Files 6-K with April Press Releases

TL;DR

Pharming Group N.V. dropped April press releases via 6-K filing.

AI Summary

Pharming Group N.V. filed a Form 6-K on April 25, 2024, to furnish press releases dated April 18-19, 2024, as Exhibits 99.1, 99.2, and 99.3. The filing is for the month of April 2024 and relates to their status as a foreign private issuer.

Why It Matters

This filing provides investors with timely updates from Pharming Group N.V. through the inclusion of recent press releases, offering insights into the company's ongoing activities and communications.

Risk Assessment

Risk Level: low — This filing is primarily administrative, providing previously issued press releases without new financial or operational disclosures.

Key Players & Entities

• Pharming Group N.V. (company) — Registrant
• April 18-19, 2024 (date) — Date of press releases
• April 25, 2024 (date) — Filing date

FAQ

From the Filing

0001828316-24-000016.txt : 20240425 0001828316-24-000016.hdr.sgml : 20240425 20240425102949 ACCESSION NUMBER: 0001828316-24-000016 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240425 FILED AS OF DATE: 20240425 DATE AS OF CHANGE: 20240425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 24873596 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 pharmingconvertiblebondref.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1, 99.2 and 99.3 to this Report on Form 6-K are press releases of Pharming Group N.V., or the Company, dated April 18-19, 2024. EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 99.2 Pharming Group announces the placement of €100 million convertible bonds due 2029 99.3 Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Sijmen de Vries Name: Sijmen de Vries Title: CEO Date: April 25, 2024 NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 Pharming Group N.V. launches new convertible bond offering and simultaneously invites holders of its outstanding €125 million 3.00% convertible bonds due 2025 to offer their convertible bonds for purchase for cash Leiden, the Netherlands, 18 th April, 2024: Pharming Group N.V. (" Pharming " or the " Company ") (Euronext Amsterdam: PHARM) launches today the issue of approximately €100 million senior unsecured convertible bonds due 2029 (the “ New Bonds ”) convertible into new and/or existing ordinary shares in the capital of the Company (the “ Shares ”) and concurrently invites current holders of its outstanding €125 million 3.00% convertible bonds due 2025 to submit offers to sell for cash. • The New Bonds are expected to be issued on 25th April 2024 (the “ Issu